Dedicated to providing the safest, highest quality products.

 

Revita™

 
 
 
 
 
Revita_Logo_FullColor w R.png
 
 

Revita is an intact human placental membrane allograft that preserves all layers of the biologic tissue and maintains the physiologic 3D architecture of the natural barrier membrane. 

What Revita Provides:

Revita provides the complete intact human placental membrane that is the physiologic tissue barrier naturally found in the body. This complete barrier containing amnion, intermediate layer and chorion retains many of the cytokines, growth factors, extracellular components, and cell communication signals the body uses to heal, protect and grow tissues.

 
 

What Makes Revita Different?

The preservation of the amniotic intermediate layer is a vital part of the membrane barrier present between the amnion and chorion layers. The intermediate layer:

  • Acts as a cushion
  • Contains hyaluronic acid (HA) + collagen
  • Contains growth factors
  • Contains glycosaminoglycans and proteoglycans
 

Uses for Revita:

Clinical applications include:

  • Wound care
  • Orthopedics
  • Spine
  • Urology
  • Plastic Surgery
  • General Surgery
  • OB/GYN
  • Ophthalmology
  • Dental

 

 
 
 

Intact Human Placental Membrane vs. Dehydrated Competitor

Using the Clearify™ processing method, Revita preserves all three layers of the amniotic membrane architecture.

 
 
 

Unprocessed Placental Membrane

Revita Preservation of 3D Architecture

  • Freeze-dried
  • Never delaminated
  • Preserves intermediate layer which contains hyaluronic acid and additional proteins

Competitor

 
 
 

To date, over 150 signaling proteins have been measured in Revita1

 
 

Revita contains many essential cytokines and growth factors including:

 (+) rating system range from 1-5 representing relative amounts present in the tissue

(+) rating system range from 1-5 representing relative amounts present in the tissue

 

Revita Sizes and Ordering Numbers:

Ordering Numbers and Sizes.png
 
 
 

The Evolution of Placental Membrane Allografts

The human placental membrane is composed of three distinct layers: the amnion, the intermediate layer, and the chorion. Millions of years of evolution has perfected this membrane, making it the ideal barrier to surround and protect a growing fetus. StimLabs’ experts sought out to preserve all three layers of the native membrane in order to maximize the components that occur naturally in the native tissue. 

 
Dates2.png
 
All3layersdropshadow.png
layer.png
 
 

The clinical use of the amniotic membrane began in the early 1900s, when physicians experimented with using the tissue as an alternative to xenografts and cadaveric skin grafts.2 Throughout the 20th century, clinicians and researchers continued exploring the medicinal benefits of amniotic tissue in a wide range of clinical applications, and by the 1990s, amniotic tissue gained broad clinical acceptance in ophthalmic surgery.2 This single layer, amnion only, graft was the first iteration in a series of advancing placental tissue processing methods.3

In 2008, Surgical Biologics, founded by John Daniel, developed the first dual layer shelf-stable placental allograft, preserving both the amnion and chorion layers of the native membrane.4 This breakthrough significantly increased the protein content over single layer placental allografts and enabled broader clinical applications.

In 2015, StimLabs developed the next-generation ClearifyTM process to retain all three layers of the native placental membrane. The Clearify process is optimized to process the amniotic and chorionic layers together, allowing the retention of the jelly-like intermediate layer which naturally lies between these membranes. Preserving all three layers of the placental membrane allows Revita to deliver the maximum concentration of components naturally found in the native tissue and provide a scaffold that mimics the natural architecture of the placental tissue.

Most placenta-based products are processed by removing the intermediate layer and retaining only the amnion and chorion. Manipulating this membrane in such a way diminishes the natural balance of therapeutic components and disrupts the inherent architecture of the tissue.

 
 

Ascent™

 
 
 
injectionpic2.png
 
 
4PointsofAScentai.png
 
 

Ascent is an injectable allograft derived from amniotic fluid, intended for homologous use. Ascent is designed to protect, cushion, lubricate, and reduce inflammation in fluid environments, such as joints and tendons. Ascent is processed using the patent-pending Selectify™ process that selects key amniotic fluid cellular components, including proteins and growth factors, and preserves the allograft in a shelf-stable format. The key benefits of Ascent are essential for tendon and joint relief:

 
reduces_inflammation.png
 

How does Ascent work?

Many different biomolecular functions trigger the inflammation and degeneration of joints and tendons. Decreased proteoglycan content, increased inflammation and anabolic factors, and increased degradative enzymes all contribute to hypertrophy. In many synovial joints, this results in cartilage degradation, a decrease in type II collagen, and fibrillation and osteophytes.5,6 Following rehydration, many components in Ascent help provide lubrication, reduce inflammation, and supplement these degenerative environments.


Injection Comparison

 
ascent_injection_comparison.png
 

 

To date, over 180 signaling proteins have been measured in Ascent1

 

Ascent contains hyaluronic acid, cytokines, and growth factors including:

 (+) rating system range from 1-5 representing relative amounts in a 15 mg dose of ascent

(+) rating system range from 1-5 representing relative amounts in a 15 mg dose of ascent

 

Ascent Sizes and Ordering Numbers:

 

For more information on Ascent, visit ascentinjection.com

1. Data on file. 2. Silini et al. The long path of human placenta, and its derivatives, in regenerative medicine. Bioeng. Biotechnol. Oct 19 2015. 3:162. 3. Tseng et al. Amniotic Membrane Transplantation for Persistent Epithelial Defects with Ulceration. American Journal of Ophthalmology, 1997; 123:202-213. 4. Daniel, John Placental tissue grafts. US 2008/0046095 A1, United States Patent and Trademark Office, 21 Feb 2008. 5. Goldring, et al. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011 Sep; 23(5): 471–478. 6. Goldring, et al. Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon MMP-13 regulation in osteoarthritis. Eur Cell Mater. 2011 Feb 24;21:202-20.
 
 

 
 

Learn more about how Revita and Ascent are revolutionizing the amniotic tissue market.